Updated on 2024/11/28

Information

 

写真a

 
GOTO SHUNSUKE
 
Organization
Kyushu University Hospital Urology Assistant Professor
School of Medicine Department of Medicine(Concurrent)
Title
Assistant Professor
Profile
泌尿器科における臨床業務 泌尿器科癌に関する基礎および臨床研究 臨床泌尿器科領域に関する講義、実習等での指導
External link

Degree

  • MD, PhD

Papers

  • Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models Reviewed International journal

    Shunsuke Goto, Yukimi Sakoda, Keishi Adachi, Yoshitaka Sekido, Seiji Yano, Masatoshi Eto, Koji Tamada

    CANCER IMMUNOLOGY IMMUNOTHERAPY   70 ( 9 )   2503 - 2515   2021.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00262-021-02853-3

  • Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients

    Tanegashima, T; Shiota, M; Tsukahara, S; Mutaguch, J; Goto, S; Kobayashi, S; Matsumoto, T; Eto, M

    PROSTATE   84 ( 14 )   1329 - 1335   2024.10   ISSN:0270-4137 eISSN:1097-0045

     More details

    Language:English   Publisher:The Prostate  

    BACKGROUND: Proton pump inhibitors (PPIs) are widely used due to their affordability and minimal severe side effects. However, their influence on the efficacy of cancer treatments, particularly androgen receptor signaling inhibitors (ARSIs), remains unclear. This study investigates the impact of PPI usage on the treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: A total of 117 mCRPC patients were retrospectively analyzed and divided into two groups based on the concomitant use of PPI at the initiation of ARSI treatment: PPI+ (n = 38) and PPI- (n = 79). Patient characteristics, including age at ARSI treatment administered, prostate-specific antigen (PSA) value at ARSI treatment administered, International Society of Urological Pathology grade group at prostate biopsy, metastatic site at ARSI treatment administered, prior docetaxel (DTX) treatment, and type of ARSI (abiraterone acetate or enzalutamide) were recorded. Progression-free survival (PFS), overall survival (OS), and PSA response rates were compared between the two groups. Patients were further stratified by clinical background to compare PFS and OS between the two groups. RESULTS: The PPI- group exhibited significantly extended PFS and a trend toward improved OS. For PSA response (reduction of 50% or more from baseline), the rates were 62.3% and 45.9% in the PPI- group and the PPI+ group, respectively. For deep PSA response (reductions of 90% or more from baseline), the rates were 36.4% and 24.3% in the PPI- group and the PPI+ group, respectively. The effects were consistent across subgroups divided by prior DTX treatment and type of ARSI administered. CONCLUSIONS: The administration of PPIs appears to diminish the therapeutic efficacy of ARSIs in mCRPC patients. Further prospective studies are needed to confirm these findings and explore the biological mechanisms involved.

    DOI: 10.1002/pros.24769

    Web of Science

    Scopus

    PubMed

  • Optimization of Extended Pelvic Lymph Node Dissection Side for Prostate Cancer

    Shiota, M; Shimbo, M; Tsukahara, S; Tanegashima, T; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Hattori, K; Endo, F; Eto, M

    ANNALS OF SURGICAL ONCOLOGY   31 ( 13 )   8986 - 8992   2024.9   ISSN:1068-9265 eISSN:1534-4681

     More details

    Language:English   Publisher:Annals of surgical oncology  

    BACKGROUND: This study aimed to show the association between tumor location and laterality of positive lymph nodes by evaluating biopsy and magnetic resonance imaging (MRI) findings, and to optimize the extended pelvic lymph node dissection (ePLND) side for prostate cancer. METHODS: The study enrolled patients who underwent robot-assisted radical prostatectomy with ePLND. Tumor locations were determined according to International Society of Urological Pathology grade group 4/5 in biopsies and Prostate Imaging-Reporting and Data System category 4/5 in MRI results. The concordance of tumor location lobe and positive lymph node side with the performance of tumor location-guided ePLND for positive lymph node detection was evaluated. RESULTS: For 301 patients who underwent ePLND at Kyushu University Hospital, tumor locations determined by biopsy and MRI findings showed no lesion in 8 (2.7%) patients, unilateral lobe in 223 (74.1%) patients, and bilateral lobe in 70 (23.3%) patients. The accuracies for detection of any and all positive lymph nodes by tumor location-guided unilateral ePLND were 99.6% and 97.3%, respectively. Among the patients at St. Luke's International Hospital, the accuracies for detection of any and all positive lymph nodes by tumor location-guided unilateral ePLND were estimated to be 99.0% and 97.3%, respectively. CONCLUSIONS: This study proposed tumor location-guided ePLND according to biopsy and MRI findings. This novel strategy is expected to reduce the burden of bilateral ePLND at the cost of acceptable risk of failing to detect positive lymph nodes.

    DOI: 10.1245/s10434-024-16294-6

    Web of Science

    Scopus

    PubMed

  • Functional outcomes in robot-assisted partial nephrectomy with three-dimensional images reconstructed from computed tomography: a propensity score-matched comparative analysis

    Kobayashi, S; Tsukino, K; Mutaguchi, J; Tanegashi, T; Goto, S; Matsumoto, T; Shiota, M; Eto, M

    JOURNAL OF ROBOTIC SURGERY   18 ( 1 )   314   2024.8   ISSN:1863-2483 eISSN:1863-2491

     More details

    Language:English   Publisher:Journal of Robotic Surgery  

    Our objective was to investigate the long-term functional outcomes of robot-assisted partial nephrectomy (RAPN) combined with three-dimensional (3D) imaging. The 3D images, reconstructed using computed tomography, were introduced in RAPN procedures. The demographic, oncological, functional, and volumetric outcomes of 296 patients who underwent RAPN with and without 3D imaging between 2013 and 2021 were analyzed retrospectively. Propensity score matching (1:1) was performed to adjust for potential baseline confounders. After matching, 71 patients were allocated to each group. In the 3D RAPN (3DRPN) group, functional outcomes significantly improved: the number of patients with over 90% estimated glomerular filtration rate (eGFR) preservation rate (40 vs. 43, P = 0.044), eGFR preservation rate (88.0% vs. 91.6%, P = 0.006), the number of patients with chronic kidney disease (CKD) upstaging (26 vs. 13, P = 0.023), and split renal function preservation rate (operated kidney: 84.9% vs. 88.5%, P = 0.015). The 3DRPN group showed superiority in terms of >90% eGFR preservation (P = 0.010), CKD upstaging-free survival rates (P < 0.001), and volumetric outcomes (excess parenchymal volume: 27.9 vs. 17.7 mL, P = 0.030; parenchyma volume preservation rate: 81.6% vs. 88.8%, P = 0.006). Three-dimensional imaging was positively associated with eGFR preservation (P = 0.023, odds ratio: 2.34) and prevention of CKD upstaging (P = 0.013, odds ratio: 2.90). In this study, RAPN combined with 3D imaging underscored the preservation of eGFR > 90% and the prevention of CKD upstaging by improving the preservation rate of renal parenchyma and split renal function.

    DOI: 10.1007/s11701-024-02070-x

    Web of Science

    Scopus

    PubMed

  • Current status and future perspective of immunotherapy for renal cell carcinoma

    Blas, L; Monji, K; Mutaguchi, J; Kobayashi, S; Goto, S; Matsumoto, T; Shiota, M; Inokuchi, J; Eto, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 8 )   1105 - 1114   2024.8   ISSN:1341-9625 eISSN:1437-7772

     More details

    Language:English   Publisher:International Journal of Clinical Oncology  

    In the last decade, the standard treatment for advanced renal cell carcinoma (RCC) has evolved, mainly driven by the development and approval of immune checkpoint inhibitors (ICIs). Currently, ICI monotherapy and ICI-based combinations with tyrosine kinase inhibitors and targeted therapies against mammalian target of rapamycin or vascular endothelial growth factor have become new standard treatments for first-line and subsequent-line therapies. ICIs play an important role as an adjuvant postoperative therapy, and this field is the subject of active research. Furthermore, ongoing randomized controlled trials are investigating the clinical value of more intense treatments by combining multiple effective treatments for RCC. Additionally, novel biomarkers for prognosis have been investigated. This study reviews the current evidence on immunotherapy as a treatment for RCC patients, randomized controlled trials, and ongoing studies including RCC patients and recent findings, and discusses future perspectives.

    DOI: 10.1007/s10147-023-02446-3

    Web of Science

    Scopus

    PubMed

  • An innovate segmentation system by implementing dilated convolution and red channel enhanced images in cystoscopic images

    Mutaguchi, J; Morooka, K; Goto, S; Kobayashi, S; Matsumoto, T; Shiota, M; Inokuchi, J; Eto, M

    EUROPEAN UROLOGY   85   S377 - S377   2024.3   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate. Reviewed International journal

    @Shiota M, @Tsukahara S, @Takamatsu D, @Tanegashima T, @Ueda S, #Blas L, @Goto S, @Kobayashi S, @Matsumoto T, @Inokuchi J, @Shioyama Y, @Eto M.

    Asian J Endosc Surg   2024.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation. Reviewed International journal

    J Robot Surg   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation

    Shiota, M; Tsukahara, S; Ueda, S; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Blas, L; Monji, K; Inokuchi, J; Eto, M

    JOURNAL OF ROBOTIC SURGERY   17 ( 6 )   2721 - 2728   2023.12   ISSN:1863-2483 eISSN:1863-2491

     More details

    Language:English   Publisher:Journal of Robotic Surgery  

    The novel technique of lateral pelvic fascia preservation (LPFP) in robot-assisted radical prostatectomy (RARP) has been reported to improve urinary continence recovery. We aimed to investigate surgical and oncological outcomes after RARP using the LPFP technique and compare them with conventional RARP. This study included patients who underwent RARP with and without the LPFP technique. Time to urinary continence recovery was compared between the LPFP and non-LPFP groups using univariate, multivariate, and propensity-score matched analysis. Perioperative and postoperative outcomes were compared between the two groups using univariate analysis. We included 139 patients who underwent RARP, 68 in the LPFP group and 71 in the non-LPFP group. The LPFP technique was associated with a shorter time to urinary continence recovery, a shorter operative time and lower estimated blood loss. Surgical and oncological outcomes, including complications, pathological T-stage, surgical margin status, and biochemical recurrence-free survival, were comparable between the two groups. This study demonstrated that the LPFP technique improves urinary continence recovery and operative times without compromising surgical and oncological outcomes. The use of this technique in patients with clinically localized prostate cancer is recommended.

    DOI: 10.1007/s11701-023-01702-y

    Web of Science

    Scopus

    PubMed

  • Current evidences in the first-line treatment of metastatic non-clear cell renal cell carcinoma

    Inokuchi, J; Goto, S; Monji, K; Eto, M

    ANNALS OF ONCOLOGY   34   S1362 - S1362   2023.11   ISSN:0923-7534 eISSN:1569-8041

  • Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies. Reviewed International journal

    @Kashiwagi E, @Shiota M, @Inokuchi J, @Tsukahara S, @Imada K, @Monji K, @Goto S, @Matsumoto T, @Eto M:

    Anticancer Res   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies

    Kashiwagi, E; Shiota, M; Inokuchi, J; Tsukahara, S; Imada, K; Monji, K; Goto, S; Matsumoto, T; Eto, M

    ANTICANCER RESEARCH   43 ( 9 )   4249 - 4254   2023.9   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publisher:Anticancer Research  

    Background/Aim: Testosterone is essential for prostate cancer development and growth. This study aimed to investigate the relationship between testosterone in seminal vesicles and prostate cancer incidence and its malignant phenotype. Patients and Methods: After obtaining institutional review board approval, seminal vesicle fluid samples were collected from patients who underwent prostatectomy or cystectomy. Pathological review demonstrated that 26 patients had benign prostate tissue and 149 had prostate cancer. First, testosterone levels in seminal vesicle fluid from benign prostate and prostate cancer samples were compared. Next, the relationship between pathological stage, International Society of Urological Pathology (ISUP) score, and testosterone concentrations in seminal vesicle fluid in the prostate cancer group were examined. Results: Testosterone in seminal vesicles was significantly higher in the prostate cancer group [median (range), 1.94 (0.17-4.32) ng/ml] than in the benign prostate group (mainly bladder cancer) [1.45 (0.60-2.78) ng/ml] (p=0.001). Testosterone in seminal vesicles showed no difference in relation to pathological stage (pT2 vs. pT3) or ISUP score (12 vs. 345) (p=0.480 and p=0.964, respectively). Neoadjuvant chemotherapy for other cancers (e.g., bladder or rectal cancer) significantly reduced testosterone in seminal vesicles (p=0.013). Multivariate regression analysis revealed that testosterone in seminal vesicles was significantly correlated with prostate cancer, and not with neoadjuvant chemotherapy (p=0.023, p=0.457, respectively). Conclusion: Testosterone in seminal vesicles may contribute to prostate cancer incidence, but has no relationship with pathological grading.

    DOI: 10.21873/anticanres.16618

    Web of Science

    Scopus

    PubMed

  • Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men. Reviewed International journal

    2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men

    Blas, L; Shiota, M; Tsukahara, S; Goto, S; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Inokuchi, J; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   30 ( 7 )   600 - 604   2023.7   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publisher:International Journal of Urology  

    Objective: The precise diagnosis of prostate cancer (PC) is crucial to avoid underdiagnosis, overdiagnosis, and overtreatment. We aimed to compare clinically significant PC (csPC) detection between MRI/ultrasound fusion-targeted prostate (TBx) compared to systematic biopsy (SBx) in biopsy-naïve Japanese men. Methods: We included patients with suspect PC due to elevated PSA level or abnormal digital rectal examination, or both. csPC was defined as International Society Urological Pathology (ISUP) grade group ≥2 (csPC-A) and ISUP grade group ≥3 (csPC-B). Results: This study included 143 patients. Overall PC detection was 66.4% for SBx and 67.8% for MRI-TBx. MRI-TBx presented a significantly higher rate of csPC detection (csPC-A 67.1% vs. 58.7%, p = 0.04, and csPC-B 49.6% vs. 39.9%, p < 0.001) and significantly lower detection of non-csPC-A (0.6% vs. 6.7%). Importantly, MRI-TBx missed 4.9% (7/143) of csPC-A and only 0.7% (1/143) of csPC-B. On the other hand, SBx alone missed 13.3% (19/143) of csPC-A and 4.2% (6/143) of csPC-B. Conclusion: MRI-TBx significantly outperformed 12-cores SBx for csPC detection and decreased non-csPC detection in biopsy-naive men. Performing MRI-TBx without SBx would have missed some csPC, supporting that MRI-TBx synergizes with SBx to increase csPC detection.

    DOI: 10.1111/iju.15188

    Web of Science

    Scopus

    PubMed

  • Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy. Reviewed International journal

    Int J Urol   2023.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy

    Lee, K; Shiota, M; Takamatsu, D; Ushijima, M; Blas, L; Okabe, A; Kajioka, S; Goto, S; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Inokuchi, J; Oda, Y; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   30 ( 4 )   340 - 346   2023.4   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publisher:International Journal of Urology  

    Objectives: To investigate the impact of extended pelvic lymph node dissection (ePLND) on urinary incontinence (UI) at early post-surgery robot-assisted radical prostatectomy (RARP). Methods: Patients who underwent RARP without cavernous nerve sparing were included between 2014 and 2019. Patient data were obtained prospectively. The associations between ePLND and postoperative urinary continence were defined as a maximum of one daily pad use. International prostate symptom score (IPSS) was examined. Expression of synaptophysin and tyrosine hydroxylase (TH) in perilymph node adipose tissue (PLA) was evaluated by immunohistochemistry. Results: In total, 186 and 163 patients underwent RARP with and without ePLND. Urinary continence rate at 1 month postoperatively among patients with ePLND was lower than those without ePLND (24.1% vs. 35.1%, p < 0.05), however, not significantly different at 3, 6, and 12 months after RARP (57.4 vs. 62.6%, 73.1 vs. 74.2%, and 83.0 vs. 81.2%, respectively). Total and voiding plus postvoiding IPSS scores at 1 month were higher in patients with ePLND than in those without ePLND (14.5 ± 0.5 vs. 13.6 ± 0.6, 7.0 ± 0.3 vs. 6.2 ± 0.4, respectively, p < 0.05). In univariate and multivariate analyses, larger prostate volume and ePLND were factors associated with an increased UI rate. Among patients who underwent ePLND, synaptophysin and TH-positive nerve fibers were detected in PLA. Conclusions: Detection of synaptophysin and TH-immunopositive nerves suggested denervation of sympathetic and peripheral nerves caused by ePLND might be associated with a higher UI rate and poor urinary symptoms at an early stage after RARP.

    DOI: 10.1111/iju.15119

    Web of Science

    Scopus

    PubMed

  • Prognostic impact of CD73/adenosine receptor 2 (A2aR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features

    Takamatsu, D; Kiyozawa, D; Kohashi, K; Goto, S; Kinoshita, F; Matsumoto, T; Ri, K; Monji, K; Kashiwagi, E; Shiota, M; Inokuchi, J; Oda, Y; Eto, M

    EUROPEAN UROLOGY   83   2023.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Immunophenotype analysis of tumor-infiltrating immune cells to elucidate the mechanism of antitumor effect of IL-7 and CCL19 producing CAR-T cells against solid cancer

    Goto, S; Tamada, K; Eto, M

    EUROPEAN UROLOGY   83   2023.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Prospective study of adoptive activated αβT lymphocyte immunotherapy for refractory cancers: development and validation of a response scoring system. Reviewed International journal

    @Nonami A, @Matsuo R, @Funakoshi K, @Nakayama T, @Goto S, @Iino T, @Takaishi S, @Mizuno S, @Akashi K, @Eto M:

    2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Denervation caused by extended pelvic lymph node dissection worsens early urinary continence after robot-assisted radical prostatectomy

    Lee, K; Shiota, M; Takamatsu, D; Ushijima, M; Okabe, A; Kajioka, S; Goto, S; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Inokuchi, J; Oda, Y; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   29   22 - 22   2022.10   ISSN:0919-8172 eISSN:1442-2042

     More details

  • IL-7 and CCL19 producing CAR-T cells enhance antitumor efficacy against solid cancer by preventing antigen-loss tumor relapse

    Goto, S; Tamada, K; Eto, M

    EUROPEAN UROLOGY   81   S1635 - S1636   2022.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Human CAR-T cells producing IL-7 and CCL19 show enhanced anti-tumor efficacy against solid cancer in a PDX mouse model

    Goto, S; Tamada, K; Eto, M

    CANCER SCIENCE   113   1489 - 1489   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

    Tokunaga, Y; Sasaki, T; Goto, S; Adachi, K; Sakoda, Y; Tamada, K

    MOLECULAR CANCER THERAPEUTICS   21 ( 1 )   138 - 148   2022.1   ISSN:1535-7163 eISSN:1538-8514

     More details

    Language:English   Publisher:Molecular Cancer Therapeutics  

    Although adoptive transfer of T cells genetically engineered to express chimeric antigen receptor (CAR) or T-cell receptor (TCR) has been actively developed and applied into clinic recently, further improvement of these modalities is highly demanded, especially in terms of its efficacy. Because we previously revealed the profound enhancement of antitumor effects of CAR T cells by concomitant expression of IL7 and CCL19, this study further explored a potential of IL7/CCL19 production technology to augment antitumor effects of TCR T cells. IL7/CCL19-producing P1A tumor antigen-specific TCR T cells (7 × 19 P1A T cells) demonstrated significantly improved antitumor effects, compared with those without IL7/ CCL19 production, and generated long-term memory responses. The antitumor effects of 7×19 P1A T cells were further upregulated by combination with anti–PD-1 antibody, in which blockade of PD-1 signal in both 7×19 P1A T cells and endogenous T cells plays an important role. Taken together, our study demonstrated that concomitant production of IL7 and CCL19 by genetically engineered tumor-reactive T cells could synergize with PD-1 blockade therapy to generate potent and long-lasting antitumor immunity.

    DOI: 10.1158/1535-7163.MCT-21-0400

    Web of Science

    Scopus

    PubMed

▼display all

Presentations

  • IL-7 and CCL19 producing CAR-T cells enhance antitumor efficacy against solid cancer by preventing antigen-loss tumor relapse. International conference

    @Shunsuke Goto

    38th KOREA - JAPAN Urological Congress  2022.11 

     More details

    Event date: 2022.11

    Language:English  

    Country:Korea, Republic of  

  • 周術期における5-アミノレブリン酸投与と血圧低下に関する検討.

    @後藤駿介

    日本泌尿器腫瘍学会第8回学術集会  2022.10 

     More details

    Event date: 2022.10

    Language:Japanese  

    Country:Japan  

  • 当院における5-アミノレブリン酸による血圧低下に関する検討.

    @後藤駿介

    第60回日本癌治療学会学術集会  2022.10 

     More details

    Event date: 2022.10

    Language:Japanese  

    Country:Japan  

  • 先進医療として施行したロボット支援腹腔鏡下根治的腎摘除術および副腎摘除術の初期経験.

    @後藤駿介、@木下史生、 @松元 崇、@李 賢、 @門司恵介、@柏木英志、 @塩田真己、@猪口淳一、 @江藤正俊

    第32回九州内視鏡・ロボット外科手術研究会  2022.9 

     More details

    Event date: 2022.9

    Language:Japanese  

    Country:Japan  

  • 固形癌PDXマウスモデルを用いたIL-7/CCL19産生型ヒトCAR-T細胞による抗腫瘍効果の検討.

    @後藤駿介、@玉田耕治、 @江藤正俊

    第52回腎癌研究会  2022.7 

     More details

    Event date: 2022.7

    Language:Japanese  

    Country:Japan  

  • Anti-mesothelin human CAR-T cells producing IL-7 and CCL19 enhance antitumor efficacy against solid cancer in orthotopic and PDX mouse models. International conference

    @Shunsuke Goto

    Asian Oncology Society (AOS 2022)  2022.6 

     More details

    Event date: 2022.6

    Language:English  

    Country:Korea, Republic of  

  • RAPN術後再発症例に関する検討

    門司 恵介, 後藤 駿介, 木下 史生, 松元 崇, 李 賢, 柏木 英志, 塩田 真己, 猪口 淳一, 江藤 正俊

    腎癌研究会会報  2023.7  (一社)腎癌研究会

     More details

    Language:Japanese  

  • RAPN術後再発症例に関する検討

    門司 恵介, 後藤 駿介, 木下 史生, 松元 崇, 李 賢, 柏木 英志, 塩田 真己, 猪口 淳一, 江藤 正俊

    腎癌研究会会報  2022.7  (一社)腎癌研究会

     More details

    Language:Japanese  

  • Multilocular Cystic Renal Neoplasm of Low Malignant Potentialの1例

    中野 康弘, 小林 聡, 門司 恵介, 牟田口 淳, 後藤 駿介, 松元 崇, 塩田 真己, 猪口 淳一, 小田 義直, 江藤 正俊

    西日本泌尿器科  2024.1  (一社)西日本泌尿器科学会

     More details

    Language:Japanese  

  • MRI/ultrasound fusion-targeted生検を併用したsystematic前立腺生検の有用性についての検討

    種子島 時祥, 塩田 真己, Blas Leandro, 塚原 茂大, 牟田口 淳, 後藤 駿介, 小林 聡, 松元 崇, 江藤 正俊

    日本腎泌尿器疾患予防医学研究会プログラム・抄録集  2024.7  日本腎泌尿器疾患予防医学研究会

     More details

    Language:Japanese  

  • MRI/ultrasound fusion-targeted生検の前立腺癌検出成績

    塚原 茂大, 塩田 真己, Blas Leandro, 後藤 駿介, 木下 史夫, 松元 崇, 門司 恵介, 柏木 英志, 猪口 淳一, 江藤 正俊

    日本腎泌尿器疾患予防医学研究会プログラム・抄録集  2023.7  日本腎泌尿器疾患予防医学研究会

     More details

    Language:Japanese  

  • L43K超音波プローブアタッチメント開発における市販後調査

    小林 聡, 中楯 龍, 宮田 信一, 月野 圭治, 牟田口 淳, 後藤 駿介, 門司 恵介, 塩田 真己, 猪口 淳一, 江藤 正俊

    日本コンピュータ外科学会誌  2023.11  (一社)日本コンピュータ外科学会

     More details

    Language:Japanese  

  • IL-7/CCL19産生型CAR-T細胞は腫瘍上のantigen-lossを防ぐことで固形癌に対する優れた抗腫瘍効果を発揮する(IL-7 and CCL19 producing CAR-T cells enhance antitumor efficacy against solid cancer by preventing antigen-loss tumor relapse)

    後藤 駿介, 玉田 耕治, 江藤 正俊

    日本泌尿器科学会総会  2023.4  (一社)日本泌尿器科学会総会事務局

     More details

    Language:English  

  • cT3b腎癌に対して全身療法後にロボット支援下根治的腎摘除術を施行した1例

    和田 大和, 牟田口 淳, 塩田 真己, 平井 良樹, 上田 翔平, 塚原 茂大, 後藤 駿介, 木下 史生, 松元 崇, 李 賢, 門司 恵介, 柏木 英志, 猪口 淳一, 江藤 正俊

    西日本泌尿器科  2024.6  (一社)西日本泌尿器科学会

     More details

    Language:Japanese  

  • ALK rearrangement-associated renal cell carcinomaの1例

    猪口 淳一, 高松 大, 後藤 駿介, 門司 恵介, 柏木 英志, 塩田 真己, 孝橋 賢一, 小田 義直, 江藤 正俊

    日本癌治療学会学術集会抄録集  2022.10  (一社)日本癌治療学会

     More details

    Language:English  

▼display all

MISC

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Surgical Clinical Medicine / Urology

Clinician qualification

  • Specialist

    日本癌治療学会、日本泌尿器内視鏡・ロボティクス学会、日本泌尿器腫瘍学会

  • Specialist

    The Japanese Urological Association

Year of medical license acquisition

  • 2011